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Disease progression is one of the pivotal charac-
teristics of most multiple sclerosis (MS) subtypes. 
Apart from increasing physical disability, cogni-
tive impairment may progress over time and is 
associated with limitations in patients’ working 
and social life [Amato et al. 2001]. Neuro-axonal 
damage within the central nervous system is a key 
factor causing disability progression, also includ-
ing cognitive decline [Siffrin et al. 2010]. In order 
to delay or prevent disease progression, disease-
modifying therapies (DMTs) are employed, tar-
geting some of the detrimental physiological 
mechanisms [Gold et  al. 2010]. While DMTs 
Cognitive functions over the course of 1 year 
in multiple sclerosis patients treated with 
disease modifying therapies
Kathrin S. Utz, De-Hyung Lee, Alexandra Lämmer, Anne Waschbisch, Ralf A. Linker and 
Thomas Schenk
Abstract
Objectives: Disease-modifying therapies (DMTs) are applied to delay or prevent disease 
progression in multiple sclerosis (MS). While this has mostly been proven for physical 
symptoms, available studies regarding long-term effects of DMTs on cognitive functions are 
rare and sometimes inconsistent due to methodological shortcomings. Particularly in the case 
of fingolimod, comprehensive data on cognitive functions are not yet available. Therefore, we 
set out to reliably assess cognitive functions in patients with relapsing–remitting MS (RRMS) 
treated with DMTs over 1 year.
Methods: Cognitive functions were assessed with eight tests at three timepoints: baseline, 
6-month follow up and 12-month follow up. First, we investigated whether the stability of 
cognitive functions (i.e. not falling below the 5% cut-off in more than one test) over 1 year in 
RRMS patients (n = 41) corresponds to the stability in healthy individuals (n = 40) of a previous 
study. Second, we compared the percentage of declined and improved patients in the different 
tests. Third, we compared patients treated with fingolimod (n = 22) with patients treated with 
natalizumab (n = 11) with regard to cognitive stability. Fourth, based on the patient data, the 
Reliable Change Index was applied to compute cut-offs for reliable cognitive change.
Results: Approximately 75% of RRMS patients treated with DMTs remained stable over the 
course of 1 year. The Paced Auditory Serial Addition Test (PASAT) and the Spatial Recall Test 
(SPART), produced improvements in 12.5% and 30.6%, respectively, probably due to practice 
effects. Patients treated with fingolimod did not differ from patients treated with natalizumab 
with regard to cognitive stability.
Conclusions: Cognitive functions remain relatively stable under DMT treatment over 1 year, 
irrespective of the type of medication. Furthermore, the tests PASAT and SPART should be 
interpreted cautiously in studies examining performance changes over time. The provided RCI 
norms may help clinicians to determine whether a difference in two measurements observed 
in a RRMS patient is reliable.
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used to be administered parenterally, in 2010, the 
first new oral DMT, fingolimod, became availa-
ble, that is also assumed to exert direct effects in 
the central nervous system [Miron et  al. 2008; 
Noda et al. 2013]. Yet, a new drug will be only 
attractive if its efficacy is comparable with other 
DMTs. While this has been shown for fingolimod 
with regards a reduction in relapses and the risk 
of disability progression as measured by the 
Extended Disability Status Scale (EDSS) 
[Kappos et  al. 2010], another team found no 
effect on EDSS progression [Calabresi et  al. 
2014], and the effects on cognitive function have 
not yet been comprehensively elucidated [Lovera 
and Kovner, 2012].
The poor evidence is in part due to the fact that 
studies on the effects of DMTs on cognitive func-
tion in MS patients present contradictory find-
ings, or are difficult to interpret due to 
methodological shortcomings [Lovera and 
Kovner, 2012; Amato et al. 2013]. Another rea-
son may be the lack of cognitive tests that are spe-
cifically adapted to MS patients [Utz et al. 2013]. 
Moreover, to measure cognitive change, repeated 
testing is required. This is challenging, because 
several factors may confound the assessment of 
true cognitive change, such as random variations, 
variation due to daily fluctuations of mood, moti-
vation or alertness of patients, measurement 
errors, test characteristics, the test–retest reliabil-
ity of a measure or the statistical phenomenon of 
regression towards the mean [Heaton et al. 2001; 
Benedict and Walton, 2012; Till et  al. 2013]. 
Furthermore, practice effects may obscure the 
assessment of clinically reliable change. Notably, 
it became apparent that the Paced Auditory Serial 
Addition Test (PASAT), which is still the most 
widely used cognitive test in MS, is particularly 
prone to practice effects [Tombaugh, 2006; Utz 
et al. 2013]. Practice effects can be reduced by the 
use of parallel-test versions. However, for many 
cognitive tests, parallel versions do not exist, and 
practice effects may even be found when parallel 
versions are employed [Utz et al. 2013].
One solution to overcome these problems may be 
the computation of norms for reliable change 
based on healthy individuals. Another option is to 
determine the individual change relative to the 
variability observed in the group. The reliable 
change index (RCI) represents such an approach 
[Jacobson and Truax, 1991]. The RCI uses the 
variability in a given group to compute a cut-off 
value above which changes are considered to be 
clinically meaningful. Chelune and colleagues 
adapted the RCI method to take account of 
potential practice effects [Chelune et  al. 1993]. 
To do this, they computed the mean practice 
effect for their employed tests and subtracted 
those practice scores from the observed test 
scores. Heaton and colleagues concluded that the 
accuracy of the RCI with correction for practice 
effects is comparable with more complex regres-
sion models [Heaton et al. 2001].
So far, the RCI has only been applied in a few 
studies to assess cognitive changes in MS patients 
[Walker et  al. 2011; Barker-Collo and Purdy, 
2013; Donnchadha et al. 2013; Till et al. 2013]. 
In contrast to the available studies, we recruited a 
larger sample size (n = 41) compared with some 
studies (Walker and colleagues, n = 12, and 
Donnchadha and colleagues, n = 26) [Walker 
et  al. 2011; Donnchadha et  al. 2013], recruited 
adults, but not children or adolescents [Till et al. 
2013], and followed the course over 12 months 
compared with a 6-month follow up in one of the 
studies [Barker-Collo and Purdy, 2013]. 
Furthermore, norms for reliable change based on 
repeated testing in healthy individuals are not 
routinely provided. Hence, the purpose of the 
current study was to assess the course of cognitive 
functions in patients with relapsing–remitting MS 
(RRMS) treated with DMTs for over 1 year.
The first aim was to examine the course of cogni-
tive functions over 1 year in RRMS patients and 
compare it with the values obtained in healthy 
individuals examined in a previous study [Utz 
et al. 2013]. Second, we used our data to explore 
the course of performance in the different tests. 
Third, we compared RRMS patients treated with 
fingolimod with RRMS patients treated with 
natalizumab regarding the course of cognitive 
functions. The fourth aim was to use the RCI 
method to compute cut-offs for reliable cognitive 
change and thereby provide clinicians with norms 
that might allow them to assess how well individ-
ual patients respond to DMT treatment.
Methods
Patients
We recruited patients with RRMS, diagnosed 
according to the 2010 revised McDonald criteria, 
who have been in contact with the outpatient 
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service of the Department of Neurology of 
the Friedrich-Alexander University, Erlangen-
Nuremberg. Patients younger than 18 years, 
patients who had experienced a relapse within 30 
days prior to the investigation and patients whose 
records included a diagnosis of depression were 
excluded. Further exclusion criteria were demen-
tia, drug or alcohol abuse, high-dose steroid ther-
apy within the last 30 days, or other immune 
diseases requiring immune suppression. Written 
informed consent was obtained prior to investiga-
tion. The study was approved by the local ethics 
committee and conducted in accordance with the 
Declaration of Helsinki II.
Cognitive tests
A psychologist administered a selection of common 
neuropsychological tests at three measurement 
timepoints (baseline, 6-month follow up and 
12-month follow up). The selection of tests 
included subtests from the Brief Repeatable Battery 
of Neuropsychological Tests (BRB-N) [Rao, 
1990], the 10/36 Spatial Recall Test (SPART, 
modified) [Utz et  al. 2013] to assess visuospatial 
learning and recall, and the Paced Auditory Serial 
Addition Test 3’ (PASAT-3’) for the assessment of 
information-processing speed and selective atten-
tion. Furthermore, subtests from the German edi-
tion [Härting et al. 2000] of the Wechsler Memory 
Scale Revised Edition (WMS-R) [Wechsler, 1987] 
were used, as well as the digit span forward or 
backward and the spatial span forward or back-
ward, to assess verbal or visuospatial short-term 
memory. Verbal long-term memory was measured 
via the logical memory I subtest (modified ver-
sion) [Utz et al. 2013]. Subtests from the com-
puterized German test battery, ‘Testbatterie zur 
Aufmerksamkeitsprüfung’ [Zimmermann and 
Fimm, 2009] were conducted to assess selective 
attention (subtest ‘Go/Nogo’) and divided atten-
tion (subtest ‘geteilte Aufmerksamkeit’).
Finally, a computer-based visual search task was 
applied [Utz et  al. 2013]. Participants were 
required to search a visual target hidden amongst 
similar visual distractors. They had to indicate 
their choice by pointing to the target on the touch 
screen. Reaction (search) time (until button 
release), indicating visual attention, and movement 
time (time between button release and target 
touch), reflecting motor speed, were assessed. We 
have previously shown that the visual search task 
provided a more sensitive measure of MS-induced 
cognitive decline since it provided the best tool to 
discriminate between healthy individuals and MS 
patients. A more detailed description of the 
employed cognitive tests can be found in Utz and 
colleagues’ publication [Utz et al. 2013].
Data analysis
All analyses were performed with IBM SPSS 
Statistics 19. Descriptive statistics of the patients’ 
performance in the different tests (raw scores) at 
the three timepoints were determined. Data are 
provided for the whole patient group (n = 41), as 
well as separately for patients treated with fingoli-
mod (n = 22), patients receiving natalizumab (n 
= 11) and patients treated with interferon (n = 
7). The single patient receiving glatiramer acetate 
was only included in the data analysis of the whole 
sample, and the comparison between patients 
treated with fingolimod and patients treated with 
other therapies.
Methods for investigating the stability of cognitive 
functions. In order to investigate whether the sta-
bility of cognitive functions over 1 year in a sample 
of RRMS patients medicated with a DMT corre-
sponds to the stability in healthy individuals, we 
used a previous study’s data of healthy individuals 
[Utz et al. 2013]. In this study, 40 healthy individu-
als [12 males, 28 females; mean age, 36.3 years; 
standard deviation (SD): 11.39] were tested in the 
same tests, twice (baseline and 3–6-month follow 
up). The sample differed, but not significantly, with 
regard to age and sex distribution. Based on those 
data, percentile cut-off points for the difference 
between test scores of the 6-month follow up and 
baseline, and the difference between the 12-month 
follow up and baseline were computed. Patients 
falling outside the lower limit of the 5% interval 
were classified as cognitively declined in the respec-
tive test. There were eight tests, but some of them 
provided two parameters (e.g. reaction time and 
number of errors for Go/Nogo). In those cases, 
decline was diagnosed if a patient fell below the 5% 
cut-off in one of the parameters. This criterion was 
employed in the case of digit span, spatial span, 
SPART, and Go/Nogo.
A patient was classified as an overall ‘decliner’ if 
he or she showed significant cognitive decline in 
two or more of the eight tests. With a 5% error 
rate in each test, there is an estimated probability 
of 0.057 of finding decline due to chance in two 
or more of the eight tests. The remaining patients 
were classified as stable, including those whose 
cognitive functions improved.
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Comparison of different tests regarding improve-
ment and decline. For each of the cognitive tests, 
the percentage of patients whose performance 
improved and the percentage of those whose per-
formance declined, that is, those patients whose 
change values either exceeded the 95% cut-offs or 
fell below the 5% cut-offs of healthy individuals, 
was determined for the 12-month follow up 
period. Please note that for this analysis the cate-
gories were different from those for the stability 
analysis (see previous section). In our analysis of 
cognitive stability, we combined patients whose 
performance remained unchanged, or whose per-
formance improved within one category (‘stable’). 
For the current analysis, patients whose perfor-
mance remained unchanged (‘stable’) and those 
whose performance improved (‘improved’) were 
assigned to separate categories.
Analysis of the relationship between stability and 
type of medication. The percentage of decliners in 
the group of patients treated with fingolimod and 
patients treated with natalizumab was compared 
with Fisher’s exact test. The same was done for 
the comparison between patients treated with fin-
golimod and patients treated with other therapies 
(natalizumab, interferon, glatiramer acetate). As 
the sample size of patients treated with interferon 
was small, we did not compare all three groups 
with one another.
Computation of norms on the basis of the Reliable 
Change Index. To establish norms of reliable 
change based on the RRMS patient sample, the 
Reliable Change Index (RCI) [Jacobson and 
Truax, 1991] was calculated for the difference 
between baseline and 6-month follow-up perfor-
mance and the difference between baseline and 
12-month follow-up performance. The RCI was 
computed as follows:
Sdiff = ( )2 2Se ,
where Se is the standard error of the measure-
ment, computed on the basis of the SD of the 
patients’ baseline performance in a respective 
test (s) and the test–retest reliability (rxx) of that 
test (computed here on the basis of the correla-
tion between the patients’ baseline performance 
and their follow-up performance):
Se = s 1− rxx
We computed 90% RCI confidence intervals and 
corrected for practice effects [Shilling et al. 2005]. 
The practice effect for each test was the mean dif-
ference between the follow-up and baseline scores 
of the abovementioned sample of healthy individ-
uals of a previous study [Utz et al. 2013]. However, 
we only introduced a correction in those tests that 
had shown significant practice effects in the cited 
study. Such practice effects were found for the 
PASAT-3’ and digit span forward. The practice 
effect was 2.36 points for the PASAT-3’ and 0.68 
points for digit span forward. The 90% RCI inter-
vals were computed as follows:
RCI interval = Sdiff  1.645  + practice effect( ) ( )±
This formula allows the reader to compute an 
individual difference of the post- and pretest score 
of a given MS patient in a respective test and 
examine whether the obtained value corresponds 
to a meaningful change. If the computed value for 
the patient falls outside the limits of the confi-
dence interval, reliable improvement or decline 
can be assumed (see Table 3).
Results
Patient characteristics
Initially, we recruited 73 patients, but only data of 
patients who did not switch medication during 
the study and who participated in all three meas-
urements were included in the analysis. The final 
sample included 41 patients, meaning a loss of 
44%. Only 22 patients (initially 42) of the sample 
received first-dose fingolimod and 11 patients 
(initially 19) received first-dose natalizumab on 
the day of baseline assessment. One patient was 
treated with glatiramer acetate (since 12 months) 
and seven (initially 11) with interferon beta 1a or 
1b. Most interferon patients had already started 
treatment prior to the start of this study; one 
patient received his first dose at baseline. The 
mean duration between treatment initiation and 
baseline assessment of this group was 4.5 (range: 
0–8) months. In the fingolimod group, 20 patients 
were lost to follow up; 10 of those discontinued 
medication during the study. In the natalizumab 
group eight patients were lost to follow up; one of 
those discontinued medication. In the interferon 
group four patients were lost to follow up; none of 
those discontinued medication.
Clinical and demographical characteristics of 
the entire group and subgroups are reported 
in Table 1. The three groups did not differ 
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significantly according to age or sex distribution 
(all p > 0.05), but differed significantly with 
regard to time since first diagnosis (p = 0.019) 
and EDSS score at first measurement (p = 0.001), 
at 6-month follow up (p = 0.005) and 12-month 
follow up (p = 0.01). Time since first diagnosis 
was significantly longer in patients treated with 
fingolimod compared with patients receiving 
natalizumab (p = 0.04) and patients treated with 
interferon (p = 0.012). Baseline EDSS score was 
significantly lower in patients treated with inter-
feron than in patients treated with fingolimod (p 
< .001) and patients receiving natalizumab (p = 
0.002). This last finding is probably not surpris-
ing given the fact that fingolimod and natali-
zumab were introduced as second-line DMTs. 
The EDSS scores of patients treated with inter-
feron were also significantly lower than in patients 
treated with fingolimod at 6-month follow up (p 
= 0.001) and 12-month follow up (p = 0.002). 
Compared with the natalizumab group, patients 
treated with interferon had also significantly lower 
EDSS scores at 6-month follow up (p = 0.003), 
whereas at 12-month follow up there was only a 
trend towards a lower score (p = 0.075) for 
patients treated with interferon. It should be 
noted that mean values for the EDSS scores 
remained similar across the different assessment 
times. However, we had to contend with more 
missing values for the EDSS scores at 12-month 
follow up and it thus seems likely that the low 
statistical power for this assessment time is 
responsible for the fact that the EDSS difference 
between natalizumab and interferon failed to 
achieve statistical significance.Groups did not 
differ concerning the visual function score or the 
frequency of a functional deficit of the right arm 
(all p ⩾ 0.05).
Patients were asked during follow-up assessment 
whether a relapse has occurred. Six patients 
reported one relapse within the 12-month study 
period (three of the fingolimod group, one of the 
natalizumab group and two of the interferon 







Overall (n = 41*)
Sex: male/female 8/14 4/7 3/4 15/26
Age in years: median (range) 35 (21–60) 35 (23–51) 29 (20–48) 35 (20–60)
Time since diagnosis in months: median 
(range)
68 (10–300)# 28 (1–276) 24 (1–48) 42 (1–300)
EDSS  
 Baseline: median (range) 2.5 (1–6) n = 22 2.5 (1–4) n = 11 1.0 (1–1.5)# n = 7 2.5 (1–6) n = 41
 6-month follow up: median (range) 2.5 (1–6) n = 20 2.5 (1.5–3.5) n = 11 1.5 (0–1.5)# n = 5 2.5 (0–6) n = 37
 12-month follow up: median (range) 2.5 (2–6) n = 19 2.5 (1–3.5)  n = 10 1.5 (1–2.5)## n = 5 2.5 (1–6) n = 35
Visual function score within the EDSS  
 Baseline: median (range) 0.0 (0–4) n = 22 0.0 (0–2) n = 10 0.0 (0–1) n = 6 0.0 (0–4) n = 39
 12-month follow-up: median (range) 0.0 (0–4) n = 21 0.0 (0–2) n = 10 1.0 (0–1) n = 6 0.0 (0–4) n = 38
Functional deficit of the dominant arm 
(paresis, ataxia)
 
 Baseline, number of patients 8, n = 22 1, n = 11 0, n = 11 9, n = 41
 12-month follow up, number of patients 10, n = 22 4, n = 10 0, n = 6 14, n = 39
Medication within 6 months prior to study n = 22 n = 10 n = 6 n = 39
 None 4 4 1 9
 Interferon beta 1a 10 3 1 14
 Interferon beta 1b 2 1 4 7
 Natalizumab 3 0 0 3
 Glatiramer acetate 2 2 0 5
 Fingolimod 0 0 0 0
 Azathioprine 1 0 0 1
* Including the patient treated with glatiramer acetate; #group differed significantly (p < 0.05) from the other two groups; ##group differed  
significantly from the fingolimod, but not the natalizumab group; EDSS, Extended Disability Status Scale. In some cases, n differed from the group 
n given in the first line due to missing data. Therefore, those changed n are indicated in the respective table cells.
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group). One patient treated with fingolimod 
reported three relapses. The remaining 35 
patients reported 0 relapses. None of the patients 
was tested during an acute relapse.
Stability of cognitive functions
Table 2 shows the mean and standard deviations 
of raw scores for the subgroups and the whole 
patient group.
Only 11 of the 41 RRMS patients (26.8 %) were 
classified as decliners after the 6-month follow 
up, whereas the majority of patients remained sta-
ble (73.2 %, including improvement). Similar 
results were observed after 12 months. Only 10 
RRMS patients (24.4 %) showed significant cog-
nitive decline, whereas 75.6 % remained stable or 
even improved in their cognitive performance. 
There was no significant correlation between 
EDSS change and cognitive change over 1 year (r 
= 0.12, p = 0.52).
Percentage of improved and declined patients 
in the different tests
For each of the cognitive tests, the percentage of 
improved and declined patients was determined 
for the 12-month follow up in order to explore the 
course of performance in the different cognitive 
measures (see Figure 1).
It is noteworthy that the percentage of improved 
patients is surprisingly large for the SPART and 
the PASAT (five times more improvers than 
decliners for the SPART and twice as many in the 
case of the PASAT). We will offer some explana-
tion for this in the discussion section.
Relationship between stability and type of 
medication
In order to investigate whether the stability of 
cognitive function depends on the type of DMT, 
a Fisher’s exact test was computed comparing the 
percentage of decliners in the groups of patients 
treated with fingolimod and patients treated with 
natalizumab.
There was no significant association between 
type of medication and whether or not patients 
showed declined or stable cognitive functions 
after 6 or 12 months (where p > 0.99 in both 
instances, using the two-tailed Fisher’s exact 
test). Figure 2 shows the percentage of patients 
showing either declined or stable (including 
improved) cognitive functions for patients treated 
with fingolimod (n = 22) and patients treated 
with natalizumab (n = 11).
As there were large differences with regard to 
sample size between the fingolimod and natali-
zumab group, we also compared the fingolimod 
group (n = 22) with the combined group of 
patients treated with other DMTs (n = 19).
There was also no significant association between 
type of medication and whether or not patients 
showed declined or stable cognitive functions 
after 6 or 12 months (p > 0.05 in both cases, 
using two-tailed Fisher’s exact test).
Reliable change intervals as norms
To establish norms of reliable change based on 
the RRMS patient sample, the Reliable Change 
Index (RCI) was calculated for the difference 
between baseline and 6-month follow up perfor-
mance and the difference between baseline and 
12-month follow up performance. Afterwards, 
90% RCI confidence intervals were computed 
and corrected for practice effects. Table 3 shows 
the reliable change intervals for each test, sepa-
rately for the 6- and the 12-month follow up.
Discussion
We assessed cognitive functions over 1 year in 
patients with RRMS treated with DMTs. Overall, 
cognitive function remained relatively stable over 
1 year (75.6 %). This stability did not depend on 
the type of medication.
There are recent studies suggesting improving or 
stabilizing effects of interferon beta [Lacy et  al. 
2013; Patti et al. 2013; Mokhber et al. 2014] or 
natalizumab [Holmen et  al. 2011; Lang et  al. 
2012; Wilken et al. 2013; Iaffaldano et al. 2014] 
on cognitive functions.
Regarding natalizumab, Holmen and colleagues 
observed an improvement in the Symbol Digit 
Modalities Test in patients treated with natali-
zumab over 24 months [Holmen et al. 2011]. Lang 
and colleagues found stabilizing and improving 
effects of natalizumab on a selection of memory 
and attention tests, including PASAT [Lang et al. 
2012]. Wilken and colleagues observed a stabiliza-
tion or improvement in computer-based assessed 
cognitive functions over 1 year in patients treated 








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Therapeutic Advances in Neurological Disorders 9(4)
276 http://tan.sagepub.com
with natalizumab [Wilken et  al. 2013]. Finally, 
Iaffaldano and colleagues reported an improve-
ment of cognitive functions measured with the 
Brief Repeatable Battery and the Stroop test over 2 
years [Iffaldano et  al. 2014]. However, since in 
those previous studies no data on repeated testing 
from healthy subjects could be provided, it is dif-
ficult to establish to what extent those stabilizing 
Table 3. Reliable change intervals based on data of the whole patient sample.
Measure 6-month follow up: baseline 12-month follow up: baseline
SPART –9.29 ⩾ x2 – x1 ⩽ +9.29 –9.55 ⩾ x2 – x1 ⩽ +9.55
SPARTDR –3.67 ⩾ x2 – x1 ⩽ +3.67 –3.56 ⩾ x2 – x1 ⩽ +3.56
PASAT-3’ –10.88 ⩾ x2 – x1 ⩽ +15.60* –10.49 ⩾ x2 – x1 ⩽ +15.21*
Digit span forward –1.75 ⩾ x2 – x1 ⩽ +3.11* –1.77 ⩾ x2 – x1 ⩽ +3.13*
Digit span backward –2.64 ⩾ x2 – x1 ⩽ +2.64 –2.47 ⩾ x2 – x1 ⩽ +2.47
Spatial span forward –3.33 ⩾ x2 – x1 ⩽ +3.33 –2.71 ⩾ x2 – x1 ⩽ +2.71
Spatial span backward –3.45 ⩾ x2 – x1 ⩽ +3.45 –3.15 ⩾ x2 – x1 ⩽ +3.15
Logical memory I –9.77 ⩾ x2 – x1 ⩽ +9.77 –11.03 ⩾ x2 – x1 ⩽ +11.03
Go/Nogo: reaction time –88.51 ⩾ x2 – x1 ⩽ +88.51 –98.60 ⩾ x2 – x1 ⩽ +98.60
Go/Nogo: errors –3.49 ⩾ x2 – x1 ⩽ +3.49 –3.15 ⩾ x2 – x1 ⩽ +3.15
Divided attention: omissions –6.81 ⩾ x2 – x1 ⩽ +6.81 –9.70 ⩾ x2 – x1 ⩽ +9.70
Visual search: reaction time –409.80 ⩾ x2 – x1 ⩽ +409.80 –414.96 ⩾ x2 – x1 ⩽ +414.96
SPART, Spatial Recall Test; SPARTDR, delayed recall of the Spatial Recall Test; PASAT-3’, Paced Auditory Serial Addition 
Test 3’; Go/Nogo, selective-attention test; x2, patient’s follow-up test score; x1, patient’s baseline test score; *corrected 
for practice effects. If the computed value for the patient falls outside of the limits of the confidence interval, reliable 
improvement or decline can be assumed. Note that for some tests, a higher score indicates a worse, and a lower score, 
a better performance (Go/Nogo, divided attention and visual search), thus, reliable decline has occurred if x2 – x1 exceeds 
the upper limit of the interval and reliable improvement has occurred if x2 – x1 falls below the lower limit of the interval.
Figure 1. Proportion of improved (i.e. exceeding 
the 95% interval) and declined (i.e. falling outside 
the lower limit of the 5% interval) patients for the 
different tests (12-month follow up). The whole 
sample was considered (n = 41), except for SPART 
(one missing, because this test was included in the 
protocol after the first patient was examined) and 
PASAT (five missing due to exclusion of patients 
having to do the test again). The proportion of stable 
patients is not depicted.
effects or improvements may have been due to 
practice effects.
There is no study available comprehensively 
investigating the effects of fingolimod on cogni-
tive functions. There are only two studies show-
ing stability or improvement in the Multiple 
Sclerosis Functional Composite (MSFC) in MS 
patients treated with fingolimod [Cohen et  al. 
2010; Kappos et  al. 2010]. The MSFC is an 
instrument for evaluating disability in MS, includ-
ing the PASAT as cognitive measure. However, 
no separate results for the PASAT are presented. 
Given that the PASAT is prone to practice effects 
[Tombaugh, 2006; Utz et al. 2013] a better per-
formance at follow up may not necessarily indi-
cate real cognitive improvement. The strength of 
our study is that we control for practice effects by 
defining cognitive change as exceeding the change 
that is expected in healthy individuals repeatedly 
tested in the same tests. Furthermore, we com-
pared patients treated with fingolimod with 
patients treated with natalizumab and found no 
difference between groups. Admittedly, those 
results are rather exploratory, since subsample 
sizes are small and not perfectly matched.
When comparing the different cognitive tests 
regarding the percentage of improved versus 
declined patients after 12 months, the rate of 
improved patients strongly exceeded the rate of 
declined patients in the SPART and PASAT. As 
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in MS, more likely a decline of cognitive functions 
is expected, and as the percentage of decliners was 
higher for the other memory tests, it is plausible 
that the high percentage of improvement in the 
SPART is an artefact. Regarding the measures of 
attention, there was a somewhat mixed picture of 
more improved compared with declined patients 
in the selective- and divided-attention tasks, but 
conversely so, in the visual-search task. 
Nevertheless, the difference between the percent-
age of improved and declined patients was consid-
erably larger for the PASAT compared with 
selective- and divided-attention tasks. Thus, it is 
very likely that the improved performance in the 
third test session after 12 months in those tests is 
in large part due to unspecific effects, such as 
practice effects. However, it should also be noted 
that while practice effects may play a role, they 
probably do not explain the entire extent of the 
observed improvements. Penner and colleagues 
reported stronger improvements in the PASAT in 
patients treated with interferon beta-1b as com-
pared with an untreated control group [Penner 
et al. 2012]. Clearly, practice effects cannot solely 
explain these findings.
Nevertheless, substantial practice effects have 
already been reported for the PASAT before 
[Tombaugh, 2006; Utz et al. 2013] and the ques-
tion remains as to why the figures for PASAT and 
the SPART suggest an increased susceptibility for 
practice effects despite our best efforts to control 
for practice effects on the basis of data from healthy 
control participants. One explanation seems to be 
that practice effects are more pronounced for MS 
patients as compared with healthy controls. It is 
known that the magnitude of practice effects is 
influenced by the characteristics of the subjects 
and tests. They are, for instance, larger in younger 
subjects or in tests involving problem solving and a 
great degree of novelty [Heaton et al. 2001]. It has 
been hypothesized that improved cognitive perfor-
mance during DMT treatment may be due to 
enhancement of neural networks involved in prac-
tice effects [Lovera and Kovner, 2012]. 
Furthermore, it is noteworthy that five patients 
refused to do the PASAT again at follow-up test-
ing because they experienced it as very stressful. 
This observation is in line with reports in the litera-
ture about the arousal of frustration and aversion 
on the patient’s side caused by PASAT [Tombaugh, 
2006]. To sum up, our results contribute to the 
increasing evidence that the PASAT is not suitable 
for assessing the course of cognitive functions 
[Tombaugh, 2006; Utz et al. 2013].
The same seems to be the case for the SPART 
that is like the PASAT part of the BRB-N (Rao, 
1990). Thus, healthy individuals may not be the 
ideal norm group for cognitive function in MS 
patients, as practice effects may be stronger in the 
latter group and thus mask cognitive decline. For 
this reason, we recommend the use of the confi-
dence intervals based on the RRMS sample. 
These intervals give an indication of the amount 
of change that is expected and thus, conversely, 
can also give an indication of when a given change 
falls outside the expected range, and thus consti-
tutes evidence of either meaningful improvement 
or meaningful decline.
Figure 2. Percentage of patients showing either declined (i.e. falling outside the lower limit of the 5% interval 
in two or more tests) or stable (including improved) cognitive functions for patients treated with fingolimod 
(n = 22) and patients treated with natalizumab (n = 11).
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The following potential limitations to our study 
should be noted. First, the period of 1 year is rela-
tively short. Possibly, differences in cognitive 
functions between patient groups will only be 
detectable after a longer treatment period. 
Second, we did not present MRI data that would 
have allowed the comparison of brain lesions with 
change in cognitive functions. Third, the overall 
sample size is relatively small and only RRMS 
patients were included, thus limiting our ability to 
generalize our findings to the MS population at 
large. Also the fact that about 44% of the initial 
sample was not included due to discontinuation 
of medication or loss to follow up may contribute 
to this limitation. Especially in the fingolimod 
group, half of the patients who were lost to the 
follow-up study had discontinued with their med-
ication. We cannot rule out the possibility that 
this significant dropout rate may have led to some 
distortion of the results. Furthermore, the patient 
subgroups were not perfectly matched regarding 
sample size and baseline characteristics. Time 
since first diagnosis was significantly longer in 
patients treated with fingolimod compared with 
the other groups, and baseline EDSS scores were 
significantly lower in patients treated with inter-
feron than in the other groups. This last finding is 
probably not surprising since interferon is typi-
cally the first DMT offered, whereas the other 
two drugs are typically offered after treatment 
with another DMT proved unsatisfactory.
The fact that fingolimod patients show longer dis-
ease duration but similar age and EDSS scores 
compared with patients treated with natalizumab 
might imply a milder disease course (i.e. earlier 
onset, but similar EDSS). It is likely that this is the 
result of a self-selection process. When the study 
started, fingolimod was new and used as second-
line DMT. Possibly, patients suffering longer 
from the disease and thus having more experi-
ences with DMTs were more likely to choose an 
oral DMT as a second-line DMT. In contrast, 
patients with a more accelerated disease course 
may have opted for natalizumab as the more 
established second-line DMT. This might explain 
the difference in disease duration for patients on 
fingolimod versus patients on natalizumab. 
Furthermore, whereas patients treated with fin-
golimod or natalizumab received their first dose at 
baseline assessment, therapy of patients in the 
interferon group had started about 4.5 months 
before. Therefore, interferon had longer time to 
affect cognitive functions compared with the other 
two DMTs, which might have influenced the 
results. This is particularly relevant for the com-
parison between the groups.
Unfortunately, our study did not include an 
untreated patient control group. Such a group 
could have provided us with a baseline for the rate 
of change expected in the absence of treatment 
and thus would have allowed us to estimate more 
precisely the extent to which DMTs can modify 
the cognitive change expected in MS patients. 
However, an untreated control group would have 
been difficult to recruit, as typically, patients 
come to our centre to receive treatment. Denying 
treatment to patients who wanted to be treated 
would have been ethically unacceptable in the 
context of our study. Moreover, recruiting only 
those patients who themselves were not interested 
in receiving treatment would have resulted in a 
small and unrepresentative sample. Without such 
a control patient group we can only make state-
ments about the cognitive stability that is observed 
in DMT-treated patients. Nevertheless, such 
information can be quite valuable since it pro-
vides a yardstick against which the response of 
individual patients to DMT can be judged.
In conclusion, we found that a majority (approxi-
mately 75%) of RRMS patients treated with 
DMTs remain stable over the course of 1 year. 
The specific type of DMT applied did not affect 
this finding. We also found that two of the most 
frequently used cognitive tests (PASAT and 
SPART) produced improvements in a surprisingly 
large proportion of patients. We assume that these 
improvements are most likely indications of prac-
tice effects and not markers of amelioration. 
Accordingly, these two tests should be treated with 
caution in studies examining performance changes 
over time. Finally, our study yielded confidence 
intervals that can be used to assess whether an 
observed cognitive change in a given MS patient 
should be seen as reliable sign of change or can be 
discounted as expected performance fluctuation.
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